Home › Research › Down syndrome and Alzheimer's
Amyloid age and tau PET timeline to symptomatic Alzheimer’s disease in Down syndrome
Schworer EK, Zammit MD, Wang J, Handen BL, Betthauser T, Laymon CM, Tudorascu DL, Cohen AD et al.. medRxiv, 2024-08-09
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Adults with Down syndrome (DS) are at risk for Alzheimer’s disease (AD). Recent natural history cohort studies have characterized AD biomarkers, with a focus on PET amyloid-beta (Aβ) and PET tau. Leveraging these well-characterized biomarkers, the present study examined the timeline to symptomatic AD based on estimated years since reaching Aβ+, referred to as “amyloid age”, and in relation to tau in a large cohort of individuals with DS.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 167 participants. This cohort study of 167 adults with Down syndrome examined the timeline to symptomatic Alzheimer's disease based on estimated years since reaching amyloid positivity and in relation to tau. It describes biomarker timing only and tests no treatment or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Schworer, E. K., Zammit, M. D., Wang, J., Handen, B. L., Betthauser, T., Laymon, C. M., et al. (2024). Amyloid age and tau PET timeline to symptomatic Alzheimer’s disease in Down syndrome. medRxiv. https://doi.org/10.1101/2024.08.08.24311702
Vancouver
Schworer EK, Zammit MD, Wang J, Handen BL, Betthauser T, Laymon CM, et al. Amyloid age and tau PET timeline to symptomatic Alzheimer’s disease in Down syndrome. medRxiv. 2024. doi:10.1101/2024.08.08.24311702.
BibTeX
@article{schworer2024-f00bce0d,
author = {Schworer, E. K. and Zammit, M. D. and Wang, J. and Handen, B. L. and Betthauser, T. and Laymon, C. M. and Tudorascu, D. L. and Cohen, A. D. and others},
title = {{Amyloid age and tau PET timeline to symptomatic Alzheimer’s disease in Down syndrome}},
journal = {medRxiv},
year = {2024},
doi = {10.1101/2024.08.08.24311702},
url = {https://doi.org/10.1101/2024.08.08.24311702}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Recent natural history cohort studies have characterized AD biomarkers, with a focus on PET amyloid-beta (Aβ) and PET tau.
- Leveraging these well-characterized biomarkers, the present study examined the timeline to symptomatic AD based on estimated years since reaching Aβ+, referred to as “amyloid age”, and in relation to tau in a large cohort of individuals with DS.
- Methods In this multicenter cohort study, 25 – 57-year-old adults with DS (n = 167) were assessed twice from 2017 to 2022, with approximately 32 months between visits as part of the Alzheimer Biomarker Consortium - Down Syndrome.
- Adults with DS completed amyloid and tau PET scans, and were administered the modified Cued Recall Test and the Down Syndrome Mental Status Examination.
Why it matters
This cohort study of 167 adults with Down syndrome examined the timeline to symptomatic Alzheimer's disease based on estimated years since reaching amyloid positivity and in relation to tau. It describes biomarker timing only and tests no treatment or prevention.
Study details
- Study designcohort study
- Participants167
- Evidence strengthModerate
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 34 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 32 of the 94 points we could judge it on, which is 34 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 167 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Sigan L. Hartley: h-index 43 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Cambridge: institution h-index 1,973 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 32 / 94 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 32 of the 94 points we could judge it on is 34 out of 100. |
| Total | 34 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.